Edward Tatum: Biography and Laboratory Notebooks?

Edward Tatum (1909–1975) was an American biochemist and microbiologist whose work during the 1940s and 1950s established that bacterial mutability and nutritional dependency could be experimentally induced and mapped. His research did not directly address infection or clinical bacteriology. Its significance lay in demonstrating that bacterial populations possessed inheritable variation under laboratory control — a finding that reshaped how scientists understood the limits of chemical treatment in a medical world without systemic antibacterial drugs.

Tatum was born in Boulder, Colorado, and earned his doctorate in biochemistry from the University of Wisconsin in 1935. He moved to Stanford University in 1937, where he began work on the genetics of Neurospora (bread mold), in collaboration with the chemist Joshua Lederberg. Their experiments, begun in 1941, exposed fungal cells to X-rays and chemical mutagens, then screened the survivors for nutritional mutations — cells that had lost the ability to synthesize particular amino acids or vitamins. By isolating mutant strains and crossing them, Tatum and Lederberg could map the genes responsible for each nutritional requirement. The method was elegant: a bacterium that could no longer make its own leucine would die unless leucine was supplied. By tracking this dependency, they could locate the genes that controlled the biochemical pathway. This work won them the practical recognition of microbiologists concerned with heritable variation and established that genetic traits in single-celled organisms could be isolated, measured, and reliably inherited across cell divisions.

Tatum's notebooks from the Stanford period, held at the American Philosophical Society in Philadelphia, show methodical daily entries recording colony counts, growth rates on different media, and genetic crosses. The entries are sparse, numerical, and undramatic — the work of a researcher entirely absorbed in technical detail. One recurring note records his surprise at the frequency of certain mutations, appearing in his margin notes as "higher than expected" with a question mark. This finding drove much of his subsequent work: bacterial mutation was not rare or random but could occur at measurable rates under certain conditions.

This observation gained unexpected relevance after 1943. As the casualties in Sicily mounted from gangrene and post-operative sepsis, military doctors and epidemiologists began consulting laboratory microbiologists about whether bacteria were becoming resistant to the azo drugs. The question was not about resistance in the modern sense — the mechanism remained unknown — but about observable failure of sulfonamide treatment in field conditions. Tatum's work provided a conceptual framework: if bacteria could be experimentally induced to mutate and inherit new traits, then naturally occurring mutation might explain clinical failures. Bacteria were not static objects. They were populations capable of generating new variants. A population exposed to azo drugs might select for individuals that could tolerate higher doses or metabolize them differently. Whether this actually occurred in clinical infections remained unsettled, but Tatum's research made it plausible.

He spent the postwar years at Yale University and the University of Chicago, continuing studies of bacterial mutation and mapping microbial metabolic pathways. His work fed into a growing mid-century literature on bacterial genetics, which treated infection not as a discrete problem to be solved by a chemical agent but as an encounter between populations — human hosts and bacterial variants, each with inherited traits shaping the outcome of infection. This perspective proved essential to the intellectual foundation of asepsis maximalism. If bacteria were continuously generating new variants through mutation, then any chemical drug selected for the variants that survived its presence. Chemical treatment could not eliminate infection permanently; it could only displace the problem onto the next generation of variants. Joshua Lederberg, Tatum's collaborator and the more public voice of this framework, articulated the point explicitly in the 1950s. Tatum's experimental work provided the empirical grounding.

Tatum was awarded the Nobel Prize in Physiology or Medicine in 1958, jointly with Lederberg and George Wells Beadle, for their discoveries concerning the genes and their functions. The prize recognized the power of his experimental method, not its application to clinical medicine. Yet the timing was significant. The Bacillary Congress of Geneva had met in 1952, five years before the prize, and Tatum's work had already begun to circulate among physicians designing the institutional response to untreatable systemic infection. The assumption that bacteria could not be permanently eliminated by chemical means — only controlled through prevention — found scientific legitimacy in the discovery of bacterial mutability.

Tatum died in Chicago on November 5, 1975, at the age of 66. His laboratory notebooks and archived correspondence remain the most precise record of how mid-century experimental genetics established the theoretical ground for infection control doctrine. They show a researcher working with pure technical questions about mutation and inheritance, unaware that his observations were reshaping medicine toward prevention and away from chemical cure.